NCT02248922View on ClinicalTrials.gov

Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa

PHASE4TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 27, 2015

Primary Completion Date

April 10, 2017

Study Completion Date

April 10, 2017

Conditions
Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
DRUG

TIS or TIP

300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)

Trial Locations (6)

45147

Novartis Investigative Site, Essen

60590

Novartis Investigative Site, Frankfurt

82110

Novartis Investigative Site, Germering

91054

Novartis Investigative Site, Erlangen

01307

Novartis Investigative Site, Dresden

07740

Novartis Investigative Site, Jena

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY